Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gedeptin + Fludarabine in Recurrent Head and Neck Cancer
NCT03754933Phase 2Completed
- Sponsor
- GeoVax Labs, Inc.
- Start
- Feb 2019
- Primary completion
- Dec 2023
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of Gedeptin in head and neck cancer (HNC), sponsored by GeoVax Labs, Inc.. Started Feb 2019; status: completed.
02
Drugs
Gedeptin
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT03754933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03754933.